Did You Know?

Editor’s Picks

Latest News

Medical Care Technologies Inc. (OTCID:MDCE) Follows Q3 Profit Surge With Confirmed Software Development and Expanding Subsidiary Activity

270% Net Income Increase in Q3 Supported by Active $250,000 Software Agreement, $20M Collectibles Partnership, and Ongoing Authentication Work MESA,...

Sharecare Integrates IDMe into AskMD, Providing Over 100 Million Americans a Seamless, Secure Way to Access Personalized Health Guidance

AskMD's identity verification capabilities expanded to include both IDMe and CLEAR, following the same secure, patient-centered access CMS offers on...

Aptevo Provides 3Q26 Business Update Highlighting Growing Momentum for Mipletamig and Reports Third Quarter Financial Results

Mipletamig achieves 79% remission rate in high-risk TP53-mutated AML, nearly double the published historical benchmarkTen of 47 patients receiving mipletamig...

Sharecare Partners With HomeTown Health to Bring AskMD, Funded Through the GREAT Health Program, to More Rural Hospitals and Patients Across Georgia

Selected by Georgia DCH as the patient engagement platform of the GREAT Health Program, AskMD by Sharecare helps people better...

CNS Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Progress in Establishing Transformative Therapeutic Pipeline

Company has been exploring multiple acquisition and licensing opportunities, with the goal of securing first transaction by year-end$17.2 million cash...

Arexera Therapeutics Highlights Potentially Best-in-Class Preclinical Profile and Initiates Clinical Development for ATL-101 in Huntington’s Disease

– ATL-101 achieved robust (~80%) and durable (> 6 months after single administration) HTT lowering in the striatum, the key...

Rejuvenate Biomed Completes Last Patient Visit in Phase 2 Trial of RJx-01 in COPD-Related Muscle Weakness and Advances Regulatory Discussions for Sarcopenia

Last patient has completed the final study visit in the Phase 2 trial in older adults with COPD-induced muscle weakness,...

Oculis Announces FDA IND Clearance Enabling Acceleration of Privosegtor Development Program in Acute Multiple Sclerosis Relapses

FDA IND clearance opens a new era for Oculis in neurology, initiating clinical development in acute MS relapses by building...

Oculis Announces FDA IND Clearance Enabling Acceleration of Privosegtor Development Program in Acute Multiple Sclerosis Relapses

FDA IND clearance opens a new era for Oculis in neurology, initiating clinical development in acute MS relapses by building...

error: Content is protected !!